# Danatlas

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/danatlas

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.danatlas.com
- Latest round: Angel (Jun 29, 2022)
- Investors on record: 2

## About

Based in Beijing, China, and established in 2021, Danatlas is a developer of anticancer drugs that focuses on the R&D of new drugs for tumors and other diseases. Founder, Chairman and CEO, Zhou Wenlai, holds a PhD in Molecular Biology from the University of Melbourne and a postdoctoral fellow from the University of California, San Diego. He was formerly Chief Biologist and Senior Vice President of Jacobs Pharmaceuticals and Director of the Oncology Division of Novartis Institutes for BioMedical Research. The company has a branch office in Boston. It was rated as a National High-tech Enterprise and Beijing Specialized, Refined, Featured and Original SMEs. In March 2025, it closed a venture funding led by new investor Kangjun Capital, with participation from other new investors Astra Zeneca CICC Healthcare Venture Capital Fund, Guofang Fund Management, Panlin Capital and returning investor HongShan.

Danatlas has developed a synthetic lethal drug development platform and a translational medicine platform. The company's core product is the PARG inhibitor (DAT-2645), which is undergoing a Phase I dose escalation study in China. It has multiple product pipelines, including DAT-1000, DAT-5000, DAT-6000, etc. Its platforms and products focus on cancer, inflammation, blood, metabolic diseases and other fields.

The company generates revenue by providing new drugs for tumors, inflammation, blood and other diseases.

The company will use the venture funding to promote clinical research of core pipelines, expand innovative technology platforms and global strategic layout.

## Funding rounds

- Angel, Jun 29, 2022 — MED-FINE Capital
- Seed, Mar 25, 2022 — MED-FINE Capital, Qianshan Capital

## Investors

- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Seed, Angel
- Qianshan Capital — Seed